Recombinant Human CCL5/Met-RANTES Protein Summary
Product Specifications
Ser24-Ser91, with an N-terminal Met
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
335-RM
Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein. |
Reconstitution | Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
335-RM/CF
Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA. |
Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: CCL5/RANTES
CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1 - 3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature human CCL5 shares 75% - 84% aa sequence identity with canine, cotton rat, feline, mouse, and rat CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11 - 13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14 - 16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17). The Met-RANTES preparation from R&D Systems has been shown to be a partial agonist in monocyte chemotactic assays, exhibiting an ED50 10 - 20 fold higher than that of recombinant RANTES.
- Schall, T.J. et al. (1990) Nature 347:669.
- Bacon, K.B. et al. (1995) Science 269:1727.
- Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
- Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
- Schall, T.J. et al. (1988) J. Immunol. 141:1018.
- Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
- Levy, J.A. (2009) J. Immunol. 182:3945.
- Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
- DeVico, A.L. and Gallo, R.C. (2004) Nat. Rev. Microbiol. 2:401.
- Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
- Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
- Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. 100:1885.
- von Hundelshausen, P. et al. (2005) Blood 105:924.
- von Hundelshausen, P. et al. (2001) Circulation 103:1772.
- Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
- Baltus, T. et al. (2003) Blood 102:1985.
- Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.
Citations for Recombinant Human CCL5/Met-RANTES Protein
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
7
Citations: Showing 1 - 7
Filter your results:
Filter by:
-
Kupffer Cells and Blood Monocytes Orchestrate the Clearance of Iron-Carbohydrate Nanoparticles from Serum
Authors: T Arsiwala, AS Vogt, AE Barton, V Manolova, F Funk, B Flühmann, MF Bachmann
International Journal of Molecular Sciences, 2022-02-28;23(5):.
Species: Mouse
Sample Types: In Vivo
Applications: In Vivo -
Cancer-associated fibroblast-derived CCL5 contributes to cisplatin resistance in A549 NSCLC cells partially through upregulation of lncRNA HOTAIR expression
Authors: X Sun, Z Chen
Oncology Letters, 2021-08-02;22(4):696.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Regulation of the terminal maturation of iNKT cells by mediator complex subunit 23
Authors: Y Xu, Y Sun, H Shen, Y Dai, H Liu, R Li, H Zhang, L Wu, X Zhu, X Liu
Nat Commun, 2018-09-24;9(1):3875.
Species: Mouse
Sample Types: In Vivo
Applications: In Vivo -
Brcal Defective Breast Cancer Cells Induce in vitro Transformation of Cancer Associated Fibroblasts (CAFs) to Metastasis Associated Fibroblasts (MAF)
Authors: SK Hemalatha, SK Sengodan, R Nadhan, J Dev, RR Sushama, V Somasundar, R Thankappan, A Rajan, NR Latha, GR Varghese, AP Mathew, T Somanathan, P Srinivas
Sci Rep, 2018-09-17;8(1):13903.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
CCL5/RANTES contributes to hypothalamic insulin signaling for systemic insulin responsiveness through CCR5
Sci Rep, 2016-11-29;6(0):37659.
Species: Mouse
Sample Types: In Vivo
Applications: In Vivo -
Activation of an innate immune receptor, Nod1, accelerates atherogenesis in Apoe-/- mice.
Authors: Kanno S, Nishio H, Tanaka T, Motomura Y, Murata K, Ihara K, Onimaru M, Yamasaki S, Kono H, Sueishi K, Hara T
J Immunol, 2014-12-08;194(2):773-80.
Species: Mouse
Sample Types: In Vivo
-
Peritoneal Administration of Met-RANTES Attenuates Inflammatory and Nociceptive Responses in a Murine Neuropathic Pain Model.
Authors: Liou J, Mao C, Ching-Wah Sum D, Liu F, Lai Y, Li J, Day Y
J Pain, 2012-11-23;14(1):24-35.
Species: Mouse
Sample Types: In Vivo
Applications: In Vivo
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human CCL5/Met-RANTES Protein
There are currently no reviews for this product. Be the first to review Recombinant Human CCL5/Met-RANTES Protein and earn rewards!
Have you used Recombinant Human CCL5/Met-RANTES Protein?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image